Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001127602-19-023817
Filing Date
2019-07-03
Accepted
2019-07-03 09:21:30
Documents
1
Period of Report
2019-07-01

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT form3.html 3  
1 PRIMARY DOCUMENT form3.xml 3 1416
  Complete submission text file 0001127602-19-023817.txt   2809
Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Issuer) CIK: 0000882796 (see all company filings)

EIN.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 4505 EMPEROR BLVD. SUITE 200 DURHAM NC 27703
Business Address
Sniecinski Megan (Reporting) CIK: 0001781480 (see all company filings)

Type: 3 | Act: 34 | File No.: 000-23186 | Film No.: 19940218